Eckert & Ziegler supports new radiopharmaceuticals

By AuntMinnieEurope.com staff writers

March 4, 2020 -- Isotope technology developer Eckert & Ziegler has agreed to provide financial backing for the development of two new radiopharmaceuticals for diagnosing and treating lymphoma.

The company said it will initially pay 3 million euros as part of an option agreement, which may lead in the coming years to further annual payments of 2 million to 3 million euros if milestones are met. These funds will support the production of pharmaceutical-grade material for phase I trials that have already been prepared by two investigator-led academic consortia in France and Germany targeting several forms of myeloma and lymphatic leukemia.

In addition, the money will be used for the clinical development of a complementary diagnostic radiopharmaceutical labeled with gallium-68, the firm said.


Copyright © 2020 AuntMinnieEurope.com
 

To read this and get access to all of the exclusive content on AuntMinnieEurope.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnieEurope.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: